Edition:
India

Adverum Biotechnologies Inc (ADVM.OQ)

ADVM.OQ on NASDAQ Stock Exchange Global Market

6.30USD
20 Apr 2018
Change (% chg)

$-0.15 (-2.33%)
Prev Close
$6.45
Open
$6.50
Day's High
$6.50
Day's Low
$6.25
Volume
48,576
Avg. Vol
185,914
52-wk High
$8.55
52-wk Low
$2.45

Select another date:

Wed, Mar 7 2018

BRIEF-Adverum Biotechnologies Q4 Loss Per Share $0.32

* ADVERUM BIOTECHNOLOGIES REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Adverum Biotechnologies Prices $60 Mln Public Offering Of Stock

* ADVERUM BIOTECHNOLOGIES ANNOUNCES PRICING OF $60 MILLION PUBLIC OFFERING OF COMMON STOCK

BRIEF-Adverum Biotechnologies Announces Proposed Public Offering

* ADVERUM BIOTECHNOLOGIES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Adverum Biotechnologies Extends Collaboration Agreement With Editas Medicine

* ANNOUNCES EXTENSION OF ITS COLLABORATION AGREEMENT WITH EDITAS MEDICINE INC

BRIEF-Adverum Biotechnologies Provides 2018 Outlook

* ADVERUM BIOTECHNOLOGIES INC - ADVERUM'S CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $186.6 MILLION AS OF SEPTEMBER 30, 2017.

BRIEF-Highbridge Capital Reports 5.55 Pct Passive Stake In Adverum Biotechnologies

* HIGHBRIDGE CAPITAL MANAGEMENT LLC REPORTS 5.55 PERCENT PASSIVE STAKE IN ADVERUM BIOTECHNOLOGIES INC AS OF DECEMBER 5 - SEC FILING Source text for Eikon: (http://bit.ly/2iwSEnw) Further company coverage:

BRIEF-Adverum Begins Patient Enrollment In Advance Phase 1/2 Clinical Trial

* ADVERUM BIOTECHNOLOGIES BEGINS PATIENT ENROLLMENT IN THE ADVANCE PHASE 1/2 CLINICAL TRIAL FOR A1AT DEFICIENCY

BRIEF-‍Adage Capital Partners Reports A 5.55 Percent Passive Stake In Adverum Biotechnologies As Of Nov 17, 2017

* ‍ADAGE CAPITAL PARTNERS GP, L.L.C REPORTS A 5.55 PERCENT PASSIVE STAKE IN ADVERUM BIOTECHNOLOGIES INC AS OF NOVEMBER 17, 2017 - SEC FILING​ Source text: (http://bit.ly/2hXgpom) Further company coverage:

BRIEF-Adverum Biotechnologies posts Q3 loss of $0.32 per share

* Adverum biotechnologies reports third quarter 2017 financial results and provides corporate update

Select another date: